Vemlidy is a popular brand medicine used in the treatment of chronic hepatitis B infection, which is a viral infection of the liver. It has an active ingredient Tenofovir Alafenamide, which is a nucleotide reverse transcriptase inhibitor. Gilead Sciences, Inc., one of the fastest-growing pharmaceutical company manufactures this medicine. This medicine is available in a dosage of 25 mg composed as a conventional tablet
Manufacturer: Gilead Sciences, Inc.
Active Ingredient: Tenofovir Alafenamide is used as the main active component in this medicine. This medicine is a synthetic antiviral acyclic nucleotide analog of adenosine 5-monophosphate and a nucleoside reverse transcriptase inhibitor. It shows antiviral activity against hepatitis B virus and potentially against human immunodeficiency virus. This active component is hydrolyzed and converted to tenofovir by carboxylesterase 1. Intracellular tenofovir is phosphorylated by cellular kinases to its pharmacologically active form, tenofovir diphosphate.
Indications: Tenofovir alafenamide composed of medicine is indicated for the treatment of chronic hepatitis B infection, a viral infection of the liver. Vemlidy stops or slows the growth of the virus. Chronic hepatitis infection can result in serious liver damage and liver cancer. It is not known if this medication can cure hepatitis B or can prevent also.
Action Mechanism: This given medicine contains the active component tenofovir alafenamide. This active substance is an antiviral drug, known as a nucleotide reverse transcriptase inhibitor. Vemlidy works by interfering with the normal working of an enzyme i.e. DNA polymerase that is necessary for the HBV to reproduce itself.
Dosages: Given nucleotide reverse transcriptase inhibitor medicine is made available in a dosage as given below:
- 25 mg: It is to be taken orally once a day with food as prescribed by the doctor
Note: Consult the doctor in case of renal impairment, including cases of acute renal failure, has been reported after using this medication.